Claroid Pharmaceuticals IPO (DRHP filed)
Claroid Pharmaceuticals Limited filed its draft red herring prospectus with SEBI on 6 Oct 2026. Price band, lot size and issue dates are announced only after SEBI observations and the RHP filing.
Last updated
- Stage
- DRHP Filed
- DRHP filed
- 6 Oct 2026
- Days since
- 12
- Issue size
- —
- Board
- Mainboard
- Price band
- TBA
Claroid Pharmaceuticals IPO status
Claroid Pharmaceuticals Limited filed its draft red herring prospectus (DRHP) with SEBI on . The issue can open only after SEBI issues its observations and the company files the RHP with the price band.
| DRHP filed | 6 Oct 2026 |
|---|---|
| Days since filing | 12 |
| SEBI observation | Awaited |
| Price band | TBA |
| Issue dates | TBA |
Share reservation by category
| Category | Shares Details |
|---|---|
| Qualified Institutions | Not More Than 50% of the Net Issue |
| Retail Investors | Not Less Than 35% of the Net Issue |
| Non-Institutional | Not Less Than 15% of the Net Issue |
Claroid Pharmaceuticals Limited financials
Between 31 Mar 2025 and 31 Mar 2026, Income rose from ₹100.17 Cr to ₹173.91 Cr, and profit after tax rose from ₹7.22 Cr to ₹22.7 Cr. The PAT margin for 31 Mar 2026 was 13.05%.
| Period ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 117.21 | 94.34 | 56.10 |
| Total Income | 173.91 | 100.17 | 63.61 |
| Profit After Tax | 22.70 | 7.22 | 4.12 |
| EBITDA | 40.94 | 14.35 | 11.77 |
| Net Worth | 44.38 | 21.69 | 14.47 |
| Reserve & Surplus | 29.38 | 20.19 | 12.97 |
| Total Borrowings | 27.46 | 40.54 | 29.00 |
₹ in crore, as stated in the prospectus.
Key performance indicators
| KPI | Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|---|
| ROE % | 68.73 | 39.90 | 72.53 |
| ROCE % | 52.66 | 21.74 | 21.07 |
| Debt / Equity | 0.62 | 1.87 | 2.00 |
| RoNW % | 51.16 | 33.26 | 28.44 |
| Pat Margin % | 13.06 | 7.20 | 6.47 |
Peer comparison
| Company | Face value | P/E | EPS (basic) | EPS (diluted) | RoNW | NAV |
|---|---|---|---|---|---|---|
| Claroid Pharmaceuticals Limited | 10 | — | 5.41 | 5.41 | 51.16% | 10.57 |
| Bafna Pharmaceuticals Ltd | 10 | 99.90 | 4.69 | 4.69 | 15.31% | 40.64 |
| Syncom Formulations (India) Ltd | 1 | 21.90 | 0.81 | 0.81 | 20.21% | 4.41 |
| Lincoln Pharmaceuticals Ltd | 10 | 12.60 | 43.88 | 43.88 | 11.80% | 378.25 |
From the prospectus. P/E is shown as — when earnings are zero or negative, or not reported for the issuer before listing.
Objectives
The company intends to allocate the net proceeds from the offering to the following objectives.
| Sr | Objective | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding of capital expenditure requirement for setting up of the Proposed Plant | 167.97 |
| 2 | General Corporate purposes | — |
| Total | 167.97 |
About Claroid Pharmaceuticals Limited
Incorporated in August 2018, Claroid Pharmaceuticals Limited is a pharmaceutical formulations manufacturing company engaged in the development and manufacture of generic pharmaceutical products, including tablets and ointments, as well as the encapsulation of pharmaceutical formulations into hard gelatin capsules. The Company primarily caters to semi-regulated international markets, with a particular focus on exports to countries in Africa.
The Company operates a manufacturing facility located at Pirana, Ahmedabad, Gujarat, spread across approximately 12,332 square metres. The facility comprises dedicated production, quality control, warehousing, utilities and other supporting infrastructure required for pharmaceutical manufacturing. It has an effective annual manufacturing capacity of approximately 14,400 lakh tablets, 9,360 lakh capsules and 120 lakh units of ointment. The manufacturing facility has been designed to facilitate efficient material movement and coordination across various stages of the production process.
Since commencing commercial operations, the Company has focused on maintaining product quality, regulatory compliance, product development and expanding its export-oriented business. Its manufacturing facility holds manufacturing licences under the Drugs and Cosmetics Act, State GMP certifications and various regulatory approvals, including WHO-GMP (CDSCO), NAFDAC (Nigeria), TMDA (Tanzania), RFDA (Rwanda), SBDMA (Yemen) and ZFDA (Zanzibar). These approvals support the export of the Company's pharmaceutical products to the respective international markets, subject to applicable regulatory requirements.
The Company follows a diversified product and market strategy, with its generic formulations business supported by product selection, formulation development and regulatory registrations across multiple geographies. Its operations are supported by an experienced management team and a workforce engaged across key functions, including production, packing, quality assurance, quality control, engineering, regulatory affairs, formulation and development, warehousing, finance and administration.
As of August 31, 2026, the Company had a total workforce of 203 employees across its various operational, technical, regulatory and administrative functions.
Promoters
Baiju Bhupendrabhai Desai
Soni Snehalkumar Hasmukhlal
Rushin Baijubhai Desai
Patel Shaileshbhai Arjanbhai
Patel Ghanshyam Arjanbhai
Contact details
Claroid Pharmaceuticals Limited
S.No -217/P Opp Gurukul English School
Kamod-Pirana Road, Pirana
Ahmedabad, Gujarat, 382425
Telephone: +91 80008 17999
Email: cs@claroidpharma.com
Website: https://www.claroidpharma.com/
Claroid Pharmaceuticals IPO FAQs
- Has Claroid Pharmaceuticals IPO filed for an IPO?
- Claroid Pharmaceuticals Limited filed its draft red herring prospectus (DRHP) with SEBI on 6 Oct 2026.
- When will the Claroid Pharmaceuticals IPO open?
- Issue dates are announced after SEBI observations and the RHP filing. They are not available yet.
- What is the Claroid Pharmaceuticals IPO price band?
- The price band is announced a few days before the issue opens. It is not available yet.
Details are from the draft prospectus and can change in the final RHP. This is not investment advice.